SCHEMBL214409

SCHEMBL214409

NCc1cccc(F)c1F

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 2/20 0.52
PNMT P11086 2/20 0.46
MAOB P27338 2/20 0.46
IDO1 P14902 2/20 0.43
LOXL2 Q9Y4K0 2/20 0.41
HTR2C P28335 1/20 0.41
HTR2B P41595 1/20 0.41
DPP4 P27487 1/20 0.39
CES2 O00748 1/20 0.39
BCHE P06276 1/20 0.39
CES1 P23141 1/20 0.39
MPO P05164 2/20 0.39
RIPK1 Q13546 1/20 0.39
HTR2A P28223 1/20 0.38
SLC6A4 P31645 1/20 0.38
AOC3 Q16853 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2210035 0.85 TAAR1 (0.67) TAAR1MAOBIDO1MPOHTR2A
SCHEMBL31061956 0.85 TAAR1 (0.67) TAAR1MAOBIDO1MPOHTR2A
Hydrochloric Acid SCHEMBL2211422 0.83 TAAR1 (0.64) TAAR1MAOBIDO1HTR2CHTR2B
SCHEMBL10476233 0.83 MAOB (0.50) TAAR1MAOBIDO1LOXL2MPO
SCHEMBL7052559 0.81 TAAR1 (0.48) TAAR1IDO1CES2BCHECES1
SCHEMBL3300692 0.81 MPO (0.47) TAAR1IDO1CES2BCHECES1
SCHEMBL6621 0.81
SCHEMBL30556230 0.81
SCHEMBL3672443 0.80 TAAR1 (0.48) TAAR1PNMTMAOBIDO1LOXL2
SCHEMBL14354164 0.80 TAAR1 (0.48) TAAR1PNMTMAOBIDO1LOXL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 512 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025137551-A1 AMINE PURIFICATION IN A CARBON CAPTURE METHOD USING MOF BODIES SCHLUMBERGER TECHNOLOGY CORPORATION (US) 2025-06-26 WO claimed
CN-119140080-B Titanium oxide film catalytic material for rapid high-yield synthesis of imine and preparation method and application thereof 中国科学院理化技术研究所 2025-02-11 CN claimed
CN-119140080-A Titanium oxide film catalytic material for rapid high-yield synthesis of imine and preparation method and application thereof 中国科学院理化技术研究所 2024-12-17 CN claimed
CN-105505128-B Near-infrared light response self-repairing coating and preparation method thereof 南京工业大学 2018-05-08 CN claimed
EP-2819766-B1 REMOVING SULPHUR OXIDES FROM A FLUID STREAM BASF SE (DE) 2016-05-18 EP claimed
CN-105505128-A Near-infrared light response self-repairing coating and preparation method thereof NANJING UNIVERSITY OF TECHNOLOGY 2016-04-20 CN claimed
CN-103848806-B Glucopyranosyl derivatives, its preparation method and in application pharmaceutically SUNSHINE LAKE PHARMA CO.,LTD. (CN) 2016-04-06 CN claimed
EP-2819766-A1 REMOVING SULPHUR OXIDES FROM A FLUID STREAM BASF SE (DE) 2015-01-07 EP claimed
US-20130259789-A1 REMOVING SULPHUR OXIDES FROM A FLUID STREAM RESEARCH TRIANGLE INSTITUTE (US) 2013-10-03 US claimed
WO-2013128001-A1 REMOVING SULPHUR OXIDES FROM A FLUID STREAM BASF SE (DE) 2013-09-06 WO claimed
WO-2010139288-A1 5,7-DISUBSTITUTED 3-ISOPROPYLPYRAZOLO[4,3-D]PYRIMIDINES FOR USE AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS C3 BIO GMBH (DE) 2010-12-09 WO claimed
US-20100029655-A1 Processes For The Preparation Of Anti-Viral Compounds And Compositions Containing Them LEIVERS MARTIN ROBERT 2010-02-04 US claimed
WO-2010006096-A1 PROCESSES FOR THE PREPARATION OF ANTI-VIRAL COMPOUNDS AND COMPOSITIONS CONTAINING THEM SMITHKLINE BEECHAM CORPORATION (US) 2010-01-14 WO claimed
EP-2006271-A9 SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2009-07-29 EP claimed
US-20090054401-A1 Substituted bicyclic derivatives and use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2009-02-26 US claimed
EP-2006271-A2 SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF Asahi Kasei Pharma Corporation (JP) 2008-12-24 EP claimed
US-12606541-B2 PPARg modulators and methods of use EISAI R&D MANAGEMENT CO., LTD. (JP) 2026-04-21 US disclosed
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 EP disclosed
WO-1999012912-A1 THIOUREA DERIVATIVES OR NON-TOXIC SALTS THEREOF FOR INHIBITNG RAS-TRANSFORMED CELL GROWTH YUHAN CORPORATION (KR) 1999-03-18 WO disclosed
WO-1998045268-A1 NICOTINAMIDE DERIVATIVES PFIZER PRODUCTS INC. (US) 1998-10-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054401-A1 Substituted bicyclic derivatives and use thereof LTB4R2, LTC4S, LTB4R TAAR1 1127/4885PNMT 3102/4885MAOB 880/4885
US-12606541-B2 PPARg modulators and methods of use PPARG, PPARA, PPARD TAAR1 786/4885PNMT 4606/4885MAOB 2170/4885
US-20100029655-A1 Processes For The Preparation Of Anti-Viral Compounds And Compositions Containing Them RPL35, HAVCR2, RPL5 TAAR1 4722/4885PNMT 3359/4885MAOB 947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.